Opinion

Video

Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

  1. What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
  2. What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options? 
Related Videos
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
1 KOL is featured in this series.
Screenshot of Susan Wescott, RPh, MBA
Related Content
AML | Image Credit: © Andrey - stock.adobe.com
October 30th 2024

After HMA Resistance in AML, a New Possible Therapy Option

Gayle Turim Dickstein
When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase called TOPORS may help.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Bottle of prednisone | Image Credit: luchschenF - stock.adobe.com
October 30th 2024

Prednisone Superior to Other Corticosteroids for Patients With COPD, Heart Failure

Killian Meara
Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and chronic obstructive pulmonary disease (COPD).
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Gary Cooper, MD, PhD, on an image with AJMC contributor
October 29th 2024

The Importance of Early Diagnosis of Alzheimer Disease

Greg Cooper, MD, PhD
With new therapies available to treat early stages of Alzheimer disease, recognizing the symptoms earlier is increasingly important.
Monitoring patient's heart in the ICU | Image Credit: sudok1 - stock.adobe.com
October 28th 2024

NIVO Score Accurately Predicts Mortality, Noninvasive Ventilation Failure in Patients With AECOPD

Brooke McCormick
The Noninvasive Ventilation Outcomes (NIVO) score is a reliable predictor of intensive care unit (ICU) mortality, 1-year mortality, and NIV failure in patients with acute exacerbations of COPD (AECOPD), offering valuable guidance for personalized patient management.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo